Tuesday, December 6, 2011
Merck, known as MSD outside the United States and Canada, has established an Asia research & development headquarters for innovative drug discovery and development located in Beijing, China. The new facility is part of a $1.5 billion commitment the company has made to invest in R&D in China over the next five years.
A wide range of compounds will be made available free of charge to UK medical researchers next year, following an agreement between the Medical Research Council (MRC) and AstraZeneca. Academia will be granted access to 22 compounds, developed by AstraZeneca. Through MRC funding, UK academia will conduct studies to better understand what drives a range of diseases with a view to exploring new treatment opportunities.
Schulman Associates Institutional Review Board has acquired Independent
Investigational Review Board. The transaction allows both organizations, which protect the rights of human research subjects, to provide a more comprehensive suite of review services for pharmaceutical, medical device, contract research organization and clinical research site customers.